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noted in 14/38 (37%); IFA-IgG-SFG in 7, IFA-IgG-OT in 3 and for
both in 4. Of the 14; titre of 1:128 in 2, 1:256 in 4, 1:512 in 5, >1:
1024 in 3 and 8/14 (57%) were SLE, 3/14 (21.4%%) were ITP, 2/14
(14.3%) were AIHA, 1/14 (7.1%) were polymyositis and none were
thyroiditis. 8/14 had received anti-rickettsial antibiotics during
the early stages of illness based on the clinical presentation and
high IFA-IgG titres.
Conclusion: Therewas a signiﬁcant reactivity of Rickettsial dis-
ease IFA-IgG assay in auto-immune diseases. Further studies are
needed in order to ascertainwhether this is due to recent rickettsial
infections, false positive cross reactivity of autoimmune antibod-
ies with rickettsial antigens or with cell culture nuclear antigens.
We did not carry out IFA-IgM due to non-availability and non-
affordability.
http://dx.doi.org/10.1016/j.ijid.2016.02.175
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Background: Rickettsia sp. causes rickettsioses, which despite
being among the oldest known arthropod-borne diseases, are
now recognized as important emerging vector-borne infections of
humans worldwide. In Kenya, the prevalence of these diseases is
poorly understood leading to far-reaching public health implica-
tions such as the unexplained fevers problem, some of which are
caused by different spotted fever group (SFG) rickettsiae.
Methods & Materials: We used a multi-genic approach to
identify rickettsia from 4,324 questing ticks (209 adult ticks, 586
nymphs and3,502 larvae) processed into 270pools of varying sizes,
dependingon species and life-cycle stages.Weﬁrst performedPCR-
high resolution melting point (HRM) based on Rickettsia 16S rRNA
gene followed by sequencing of unique melt proﬁles. Sequences
were identiﬁed by comparisons using BLASTn method. Thereafter,
we re-ampliﬁed and sequenced citrate synthase (gltA) and outer
membrane protein B (ompB) genes, as well as the highly variable
rpmE-tRNAfMet intergenic spacer for samples with unique rick-
ettsial 16S amplicon HRM proﬁles.
Results: We report the molecular detection of Rickettsia africae
in Amblyomma eburneum ticks and novel Rickettsia-like species in
Rhipicephalus maculatus ticks for the ﬁrst time. We detected R.
africae DNA with 99-100% identity for all the ampliﬁed gene loci
while identities of two Rickettsia-like species could not be ascer-
tained due to identical similarities associated with more than one
Rickettsia species across the ampliﬁed gene loci. Sequence analysis
of gltA gene for these two Rickettsia-like species showed 98% iden-
tity across severalRickettsia sp.The ompBgene couldnot amplify for
one of the species which also had 97% identity with R. bellii based
on the rpmE-tRNAfMet intergenic spacer sequence.
Conclusion: The detection of R. africae, an important emerging
pathogen in Sub-Saharan Africa as well as novel Rickettsia sp. with
unknown pathogenicity in this study represent signiﬁcant ﬁndings
that may explain the occurrence of some unidentiﬁed febrile ill-
nesses contributing to human morbidity. Additionally, our study
outlines the indispensable role of molecular methods in routine
surveillance to monitor both known and novel pathogens likely to
be emerging threats.
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Background: Kala-azar elimination initiative launched in 2005
in South Asia aims to reach the target by 2017. Early diagnosis and
effective treatment is one of the key strategies for control along
with integrated vector management. Single dose Ambisome (SDA)
and combination regimens are the recommended treatments in
South Asia. Our objective was to assess feasibility of using these
treatments within the public health facilities and document 12
month outcome.
Methods & Materials: This was an open label, prospective,
non-randomised, non-comparative, multicentric trial conducted at
public health facilities. The study was conducted from Aug 2012
to Sep 2015 at 02 districts (Vaishali and Saran) in Bihar and at
kala-azar referral hospital (Rajendra Memorial Research Institute
of Medical Sciences) in Patna.
In Vaishali district, patients were treated with SDA (10mg/kg)
at the District hospital and A+M (single dose Ambisome 5mg/kg +
miltefosine 7 days) at 5 primary healthcare centres (PHC). In Saran
District, M+P (Miltefosine and Paromomycin) for 10 days at district
hospital and 3 PHC.
All patientswere followedup to document outcomeat 6months
and cohort of them were followed for 12 months.
Results: 1761 patients were treated in the study, achieved cure
rate of > 99% at initial outcome (Day 10) in each treatment arm.
The cure rates at 6 months were 90.9% (95% CI 89.0-92.8) for SDA
(n=892), 88.8% (CI 85.5-92.1) for A+M (n=357) and 97.0% (CI 95.6-
98.5) for M+P arm (n=512). During 12 month FU (n=1386) there
were 11 additional relapses, 2 in SDA (n=706) and 6 in A+M (n=294)
and 3 inM+P (n=386). 12 patients developed PKDL inM+P arm, 1 in
A+M arm and 2 in SDA. Five SAE occurred in SDA arm, 2 considered
related and 3 non-related to Ambisome, all of them resolved.
